Study on Clinical Effects, Prolonged Safety and Efficacy of both Ayurveda combinations Bio-Immune as Anti-viral and Covalix Vaccoil as alternate to Vaccine of COVID-19 on exposed individuals and SARS2 nCoV contact - BICV19P

eaf BioLab Leaf Research Institute A Unit of Young Naturalist Network0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•1. Subjects must be divided into two major groups:
•A) Controlled Group
•B) Uncontrolled Group
•Control Group:
•Healthy Individuals
•Proven cases of SARS2 nCoV with or without other health issues like COPD, DM, HTN etc
•Uncontrolled Group:
•Asymptomatic patients who are not SARS2 nCoV positive, which can be either those who tested negative or normal public.

•1. Patients who are taking radiation therapy
•2. Patients with sepsis, HIV, Autoimmune
•3. Patients on ventilator (critical SARS2 nCoV patients, who used any drug in treatment process)
•4. Patients below age of 5 years
•5. Patients with nerve disorder
•6. History of receipt of blood transfusion or immunoglobulin products or expected receipt through the duration of the study
•7. Known hepatic dysfunction including known or suspected active or chronic hepatitis infection
•8. Clinically significant congenital anomaly of the respiratory tract
•9. Inability to take oral medication
•10.Prolonged QTc-interval in baseline ECG ( >500 ms)
•11. Severe renal failure characterized by chronic or acute need of hemodialysis, hemofiltration or peritoneal dialysis
•12. Need of anticoagulants, antiplatelet agents, antithrombotics and thrombolytics during the treatment period.
•13. Participation in another research study involving an investigational agent within 30 days prior to consent
•14. Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results
•15. Patients not willing to give written informed consent

发起方

eaf BioLab Leaf Research Institute A Unit of Young Naturalist Network